MedTrace Logo

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

NCT05725252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-01-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics after administration of NVP-2203.

Conditions

  • Healthy Volunteers

Interventions

DRUG

NVP-2203

NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)

DRUG

NVP-2203-R

administration of active comparator

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • Jaewoo Kim · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-28
Primary Completion
2023-06-11
Completion
2023-07-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725252 on ClinicalTrials.gov